Loading...
•
Mar 31, 2023
Nevro Q1 2023 Earnings Report
Reported first quarter 2023 financial results, provided second quarter guidance and reiterated full-year 2023 guidance.
Key Takeaways
Nevro Corp. reported a 10% increase in worldwide revenue for Q1 2023, reaching $96.3 million, with Painful Diabetic Neuropathy (PDN) indication sales growing by 160% compared to Q1 2022. The company also initiated the full launch of the HFX iQ™ Spinal Cord Stimulation System in the U.S.
Worldwide revenue for Q1 2023 reached $96.3 million, a 10% increase as reported and 11% in constant currency compared to Q1 2022.
PDN indication sales for Q1 2023 were approximately $15.6 million, a 160% increase compared to Q1 2022.
U.S. trial procedures increased by 9% compared to Q1 2022, with U.S. PDN trial procedures representing 19% of total U.S. trials in the quarter.
Net loss from operations for Q1 2023 was $36.3 million; non-GAAP adjusted EBITDA loss for Q1 2023 was $17.1 million.
Forward Guidance
Nevro expects second quarter of 2023 worldwide revenue of approximately $110 million to $112 million, or growth of 6% to 8% over prior year on a constant currency basis. The company expects second quarter of 2023 non-GAAP adjusted EBITDA to be a loss of approximately $4 million to $5 million. The company continues to expect full-year 2023 worldwide revenue of approximately $445 million to $455 million, an increase of 10% to 12% over prior year on both an as reported and constant currency basis. This full-year 2023 guidance includes approximately $75 million to $85 million of PDN indication sales, an increase of 56% to 77% over prior year. The company continues to expect full-year 2023 non-GAAP adjusted EBITDA to be a loss of approximately $5 million to $10 million, which compares to a non-GAAP adjusted EBITDA loss of $23.8 million in 2022.
Positive Outlook
- Second Quarter 2023 Revenue Guidance of $110 Million to $112 Million
- Full-Year 2023 Revenue Guidance of $445 Million to $455 Million, or 10% to 12% Constant Currency Growth Over 2022
- Full-Year Guidance Includes PDN Indication Sales of Approximately $75 Million to $85 Million, or 56% to 77% Growth Over 2022
- The full market release of the HFX iQ system continues to progress well
- The company anticipates a meaningful shift in mix to the HFX iQ product throughout 2023, which combined with the ramp-up of our Costa Rica facility, is expected to benefit gross margin beginning in the fourth quarter of this year
Challenges Ahead
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...